CN Patent

CN112423737A — 用于治疗肺高压的方法和组合物

Assigned to Abraxis Bioscience LLC · Expires 2021-02-26 · 5y expired

What this patent protects

本申请提供了治疗个体中的肺高压(例如，严重型肺动脉高压，例如，WHO功能性III或IV级肺动脉高压)的方法，其包括将有效量的包括包含mTOR抑制剂(例如，雷帕霉素或其衍生物，例如，雷帕霉素)和载体蛋白(例如，白蛋白)的纳米颗粒的组合物施用至个体。

USPTO Abstract

本申请提供了治疗个体中的肺高压(例如，严重型肺动脉高压，例如，WHO功能性III或IV级肺动脉高压)的方法，其包括将有效量的包括包含mTOR抑制剂(例如，雷帕霉素或其衍生物，例如，雷帕霉素)和载体蛋白(例如，白蛋白)的纳米颗粒的组合物施用至个体。

Drugs covered by this patent

Patent Metadata

Patent number
CN112423737A
Jurisdiction
CN
Classification
—
Expires
2021-02-26
Drug substance claim
No
Drug product claim
No
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.